Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)
This study will assess the efficacy, safety and pharmacodynamic markers of the study drug, A6, in patients with CLL and small lymphocytic lymphoma (SLL).
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|CLL|SLL
DRUG: A6
Overall response rate, International Workshop on Chronic Lymphocytic Lymphoma (IWCLL) Guidelines for response of clinical, hematological, and bone marrow features., Assessed at Day 28 of Cycle 6
Safety of A6, Nature and frequency of adverse events, Throughout 6 Cycles (6 months)|Determine IWCLL response rate in the Intent-To-Treat Population, Throughout 6 Cycles (6 months)|Determine the response in patients who received all 6 cycles of A6, 6 months|Determine progression-free survival, Throughout 6 Cycles (6 months)
In patients diagnosed with CLL or SLL, study medication will be injected subcutaneously two times a day in an outpatient setting for up to 6 cycles (28 days = 1 cycle) prior to the primary endpoint assessment.